| Name | Gatifloxacin |
| Description | Gatifloxacin (CG5501) is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. |
| In vitro | Gatifloxacin increases serum adrenaline levels in both normal and diabetic rats, and concurrently reduces serum glucose concentrations in these subjects. |
| In vivo | Gatifloxacin exhibits potent inhibitory activity against bacterial type II topoisomerases, with half-maximal inhibitory concentrations (IC50) of 13.8 mg/mL and 0.109 mg/mL for Staphylococcus aureus topoisomerase and Escherichia coli DNA gyrase, respectively. Its inhibitory effect on HeLa cell topoisomerase II is minimal, with an IC50 of 265 mg/mL. Gatifloxacin inhibits Mycobacterium tuberculosis ATCC 35801 with a minimum inhibitory concentration (MIC) of 0.125 μg/mL. When used in combination with ciprofloxacin, gatifloxacin demonstrates a synergistic effect on 19% of 31 strains of Pseudomonas aeruginosa. However, gatifloxacin's activity is two-fold lower than that of ciprofloxacin and two-fold less potent than ofloxacin against Enterobacteriaceae. Gatifloxacin shows strong antimicrobial activity against Haemophilus influenzae, Legionella, and Helicobacter pylori (MIC90s, 0.03-0.06 mg/L), and at least an eight-fold greater efficacy against Chlamydiaceae and Mycoplasmataceae (gatifloxacin MIC90s, 0.13 mg/L). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 2.33 mg/mL (6.21 mM), Sonication is recommended.
|
| Keywords | Topoisomerase | Topo IV | PD-135432 | PD135432 | N. brasiliensis | hypoglycemia | E. coli,?Pseudomonas aeruginosa,?Micrococcus luteus | conjunctivitis | CG-5501 | CG 5501 | BMS206584 | BMS 206584 | Bacterial | Antibiotic | AM1155 | AM 1155 | actinomycetoma |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Stem Cell Differentiation Compound Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | NMPA-Approved Drug Library |
United States
